General Intermediates Announces Nucleoside Breakthrough
Edmonton Pharmaceutical Manufacturer Perfects Ultra-Pure Nucleoside Production for Anti-Viral and Anti-Cancer Use
General Intermediates Canada announced recently that they have perfected work on the production of Ultra-Pure Nucleosides for use in the pharmaceutical and high-tech sensor industries.
“This is exciting stuff for us,” said Dr. Glenn Weagle, EVP of Technology for GIC. “We have confirmed our ability to produce nucleosides at greater than 99% purity. Our ultra-pure nucleosides have passed all bacterial and endotoxin standards for tissue culture.”